Emmaus Life Sciences Statistics
Total Valuation
Emmaus Life Sciences has a market cap or net worth of 549,244. The enterprise value is 31.83 million.
| Market Cap | 549,244 |
| Enterprise Value | 31.83M |
Important Dates
The next estimated earnings date is Monday, March 31, 2025.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Emmaus Life Sciences has 63.87 million shares outstanding. The number of shares has increased by 23.52% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.87M |
| Shares Change (YoY) | +23.52% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 37.01% |
| Owned by Institutions (%) | n/a |
| Float | 35.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.03 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.96, with an EV/FCF ratio of -19.83.
| EV / Earnings | -9.11 |
| EV / Sales | 1.56 |
| EV / EBITDA | 38.96 |
| EV / EBIT | n/a |
| EV / FCF | -19.83 |
Financial Position
The company has a current ratio of 0.14
| Current Ratio | 0.14 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | 27.50 |
| Debt / FCF | -20.27 |
| Interest Coverage | 0.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.03% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 385,434 |
| Profits Per Employee | -65,962 |
| Employee Count | 55 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.25% in the last 52 weeks. The beta is 6.96, so Emmaus Life Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 6.96 |
| 52-Week Price Change | -89.25% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 41.91 |
| Average Volume (20 Days) | 34,867 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Emmaus Life Sciences had revenue of 20.43 million and -3.50 million in losses. Loss per share was -0.05.
| Revenue | 20.43M |
| Gross Profit | 19.35M |
| Operating Income | 18,000 |
| Pretax Income | -3.59M |
| Net Income | -3.50M |
| EBITDA | 41,000 |
| EBIT | 18,000 |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 1.26 million in cash and 32.54 million in debt, giving a net cash position of -31.28 million or -0.49 per share.
| Cash & Cash Equivalents | 1.26M |
| Total Debt | 32.54M |
| Net Cash | -31.28M |
| Net Cash Per Share | -0.49 |
| Equity (Book Value) | -53.78M |
| Book Value Per Share | -0.84 |
| Working Capital | -54.93M |
Cash Flow
In the last 12 months, operating cash flow was -1.59 million and capital expenditures -12,000, giving a free cash flow of -1.61 million.
| Operating Cash Flow | -1.59M |
| Capital Expenditures | -12,000 |
| Free Cash Flow | -1.61M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 94.70%, with operating and profit margins of 0.09% and -17.11%.
| Gross Margin | 94.70% |
| Operating Margin | 0.09% |
| Pretax Margin | -17.55% |
| Profit Margin | -17.11% |
| EBITDA Margin | 0.20% |
| EBIT Margin | 0.09% |
| FCF Margin | n/a |
Dividends & Yields
Emmaus Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.52% |
| Shareholder Yield | -23.52% |
| Earnings Yield | -636.50% |
| FCF Yield | -292.22% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Emmaus Life Sciences has an Altman Z-Score of -14.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.97 |
| Piotroski F-Score | n/a |